Showing 1 - 8 results of 8 for search 'Jarno Hoekman', query time: 0.08s Refine Results
  1. 1
    A typology of scientific breakthroughs

    A typology of scientific breakthroughs by Mignon Wuestman, Jarno Hoekman, Koen Frenken

    Published 2020-01-01
    Get full text
    Article
  2. 2
    The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders.

    The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders. by Bauke Schievink, Hiddo Lambers Heerspink, Hubert Leufkens, Dick De Zeeuw, Jarno Hoekman

    Published 2014-01-01
    Get full text
    Article
  3. 3
    The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study

    The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study by Tom G. Jacobs, H. Hilda Ampadu, Jarno Hoekman, Alexander N. O. Dodoo, Aukje K. Mantel-Teeuwisse

    Published 2018-12-01
    Get full text
    Article
  4. 4
    Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences

    Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences by H. Hilda Ampadu, Jarno Hoekman, Daniel Arhinful, Marilyn Amoama-Dapaah, Hubert G. M. Leufkens, Alex N. O. Dodoo

    Published 2018-11-01
    Get full text
    Article
  5. 5
    Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe

    Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe by Renske M.T. ten Ham, Jarno Hoekman, Anke M. Hövels, Andre W. Broekmans, Hubert G.M. Leufkens, Olaf H. Klungel

    Published 2018-12-01
    Get full text
    Article
  6. 6
    Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study

    Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study by Gabe S Sonke, Amos J de Jong, Lourens T Bloem, Christine C van Hattem, Jolien S de Groot, Jarno Hoekman, K Esther Broekman, Paula B van Hennik

    Published 2024-11-01
    Get full text
    Article
  7. 7
    The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs

    The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs by Rick A. Vreman, Lourens T. Bloem, Stijn van Oirschot, Jarno Hoekman, Menno E. van der Elst, Hubert GM Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel-Teeuwisse

    Published 2022-05-01
    Get full text
    Article
  8. 8
    Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies

    Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies by Lourens T. Bloem, Rick A. Vreman, Niels W. L. Peeters, Jarno Hoekman, Menno E. van derElst, Hubert G. M. Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel‐Teeuwisse

    Published 2021-07-01
    Get full text
    Article

Search Tools: